# Treatment of Chronic Hepatitis C With PEG Interferon alfa2a and Ribavirin in HIV-infected Patients

> **NCT00221650** · PHASE2 · COMPLETED · sponsor: **University Hospital, Bordeaux** · enrollment: 17 (actual)

## Conditions studied

- HIV Infections
- Hepatitis C, Chronic
- Treatment Failure

## Interventions

- **DRUG:** Peginterferon alfa2a
- **DRUG:** Ribavirin

## Key facts

- **NCT ID:** NCT00221650
- **Lead sponsor:** University Hospital, Bordeaux
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-04
- **Primary completion:** —
- **Final completion:** 2004-06
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2026-05-15

## Collaborators

- Hoffmann-La Roche
- Ministry of Health, France

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00221650

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00221650, "Treatment of Chronic Hepatitis C With PEG Interferon alfa2a and Ribavirin in HIV-infected Patients". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT00221650. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*